Literature DB >> 19123477

Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.

Martin Illemann1, Nigel Bird, Ali Majeed, Ole D Laerum, Leif R Lund, Keld Danø, Boye Schnack Nielsen.   

Abstract

Metastatic growth and invasion by colon cancer cells in the liver requires the ability of the cancer cells to interact with the new tissue environment. Plasmin(ogen) is activated on cell surfaces by urokinase-type PA (uPA), and is regulated by uPAR and plasminogen activator inhibitor-1 (PAI-1). To compare the expression patterns of uPA, uPAR and PAI-1 in colon cancer with that in their liver metastases, we analysed matched samples from 14 patients. In all 14 primary colon cancers, we found upregulation of uPAR, uPA mRNA and PAI-1 in primarily stromal cells at the invasive front. In 5 of the 14 liver metastases, we found intense expression of uPAR, uPA-mRNA and PAI-1 in primarily stromal cells at the metastases periphery, and in an expression pattern similar to that found in the primary tumours. In the remaining 9 liver metastases, uPAR and uPA-mRNA were only seen associated with the presence of necrosis within the liver metastases. In addition, PAI-1-immunoreactivity was in all liver metastases seen in hepatocytes at the metastases periphery. Interestingly, the former 5 liver metastases positive for uPAR, uPA mRNA and PAI-1 at the metastasis periphery all had a predominantly desmoplastic reaction, whereas 8 of the remaining 9 showed direct contact between the cancer cells and the liver parenchyma. We conclude that there are 2 distinct patterns of expression of uPAR, uPA and PAI-1 in colon cancer liver metastases and that these correlate closely with 2 morphological growth patterns. These findings may have implication for the treatment of patients with metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19123477     DOI: 10.1002/ijc.24166

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.

Authors:  Bodil E Engelmann; Annika Loft; Andreas Kjær; Hans J Nielsen; Thomas A Gerds; Eric V Benzon; Nils Brünner; Ib J Christensen; Susanne H Hansson; Niels H Holländer; Michael H Kristensen; Johan Löfgren; Elena Markova; Carsten Sloth; Liselotte Højgaard
Journal:  Oncologist       Date:  2014-01-22

2.  The histological growth pattern of colorectal cancer liver metastases has prognostic value.

Authors:  Gert G Van den Eynden; Nigel C Bird; Ali W Majeed; Steven Van Laere; Luc Y Dirix; Peter B Vermeulen
Journal:  Clin Exp Metastasis       Date:  2012-04-03       Impact factor: 5.150

3.  Growth pattern of colorectal liver metastasis as a marker of recurrence risk.

Authors:  R L Eefsen; P B Vermeulen; I J Christensen; O D Laerum; M B Mogensen; H C Rolff; G G Van den Eynden; G Høyer-Hansen; K Osterlind; B Vainer; M Illemann
Journal:  Clin Exp Metastasis       Date:  2015-03-31       Impact factor: 5.150

Review 4.  Meeting the biologic challenge of colorectal metastases.

Authors:  Harold J Wanebo; Mark LeGolvan; Philip B Paty; Sukamal Saha; Markus Zuber; Michael I D'Angelica; Nancey E Kemeny
Journal:  Clin Exp Metastasis       Date:  2012-10-10       Impact factor: 5.150

Review 5.  Breast cancer liver metastasis: current and future treatment approaches.

Authors:  Narmeen S Rashid; Jacqueline M Grible; Charles V Clevenger; J Chuck Harrell
Journal:  Clin Exp Metastasis       Date:  2021-03-06       Impact factor: 5.150

6.  15th International Symposium on Cells of the Hepatic Sinusoid, 2010.

Authors:  Laurie D DeLeve; Hartmut Jaeschke; Vijay K Kalra; Kinji Asahina; David A Brenner; Hidekazu Tsukamoto
Journal:  Liver Int       Date:  2011-04-19       Impact factor: 5.828

7.  Bone marrow-derived myofibroblasts are the providers of pro-invasive matrix metalloproteinase 13 in primary tumor.

Authors:  Julie Lecomte; Anne Masset; Silvia Blacher; Ludovic Maertens; André Gothot; Marie Delgaudine; Françoise Bruyère; Oriane Carnet; Jenny Paupert; Martin Illemann; Jean-Michel Foidart; Ida K Lund; Gunilla Høyer-Hansen; Agnes Noel
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

8.  Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient mice.

Authors:  Annika Jögi; Birgitte Rønø; Ida K Lund; Boye S Nielsen; Michael Ploug; Gunilla Høyer-Hansen; John Rømer; Leif R Lund
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

9.  Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy.

Authors:  R L Eefsen; L Engelholm; W Alpizar-Alpizar; G G E Van den Eynden; P B Vermeulen; I J Christensen; O D Laerum; H C Rolff; G Høyer-Hansen; B Vainer; K Osterlind; M Illemann
Journal:  Cancer Microenviron       Date:  2015-08-14

10.  Tissue Inhibitor of Metalloproteinase-1 Is Confined to Tumor-Associated Myofibroblasts and Is Increased With Progression in Gastric Adenocarcinoma.

Authors:  Warner Alpízar-Alpízar; Ole Didrik Laerum; Ib J Christensen; Kjell Ovrebo; Arne Skarstein; Gunilla Høyer-Hansen; Michael Ploug; Martin Illemann
Journal:  J Histochem Cytochem       Date:  2016-07-01       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.